Acousia
Tübingen, DE · 5 known investors
Acousia Therapeutics develops small-molecule drug candidates with a dual mode of action for treating acute and chronic sensorineural hearing loss (SNHL), targeting outer hair cells in the inner ear to preserve and enhance natural hearing. The biotech company focuses on drug therapies as a first-line or complementary option to hearing aids and cochlear implants.
Founders & leadership
HL
Hubert LöwenheimFounder / Board Member
Investors · 5
In the news
Frequently asked questions
- What does Acousia do?
- Acousia Therapeutics develops small-molecule drug candidates with a dual mode of action for treating acute and chronic sensorineural hearing loss (SNHL), targeting outer hair cells in the inner ear to preserve and enhance natural hearing. The biotech company focuses on drug therapies as a first-line or complementary option to hearing aids and cochlear implants.
- Who founded Acousia?
- Acousia was founded by Hubert Löwenheim.
- Who are Acousia's investors?
- Acousia's investors include Boehringer Ingelheim Venture Fund, KfW, Creathor Ventures, LBBW Venture Capital GmbH, Esperante Ventures.
- Where is Acousia headquartered?
- Acousia is headquartered in Tübingen, DE.